Table 1 Demographic characteristics and baseline scores for health status measures and disease activity in completers and non-completers (means (SD) for continuous variables, % for counts)
Completers (n = 46)Non-completers (n = 15)
Age (years)53.6 (12.6)53.3 (10.7)
Female72%53%
Disease duration (years)6.3 (8.0)6.1 (8.9)
Rheumatoid factor positive80%87%
Erosive disease (present)50%47%
Education level high (>12 years)43%40%
Pain (100 mm VAS)47 (23)40 (23)
Fatigue (0–100 mm VAS)52 (29)37 (27)
Patient global (0–100 mm VAS)52 (25)39 (22)
MHAQ (1–4)1.7 (0.5)1.6 (0.5)
SF-36 PCS (0–100)30 (9.9)35 (6.6)
SF-36 MCS (0–100)45 (11.0)49 (8.5)
DAS285.1 (1.3)4.2 (1.3)
Glucocorticoids (current use)57%73%
NSAID (current use)29%27%
Cyclo-oxygenase 2 inhibitors (current use)5%7%
DMARD initiated at baseline:
Monotherapy65%67%
Combination11%20%
Biological agent24%13%
  • DAS28, 28-joint Disease Activity Score; MCS, mental component summary; MHAQ, Modified Health Assessment Questionnaire; NSAID, non-steroidal antirheumatic drug; PCS, physical component summary; SF-36, Short Form 36; VAS, visual analogue scale.